Corporate AACE Partnership (CAP)

What is CAP?

Founded in 1993, the Corporate AACE Partnership (CAP) is a forum whose purpose is to develop an open dialogue between industry and AACE in the furtherance of patient care. The mission of the CAP is to facilitate the improvement of endocrine patient care by working with industry in areas of mutual interest.

Current Partners

  • Abbott Diabetes Care

  • AbbVie

  • AKCEA Therapeutics

  • Amarin Pharma Inc.

  • Amgen

  • AstraZeneca

  • Boehringer Ingelheim Pharmaceuticals, Inc.

  • Corcept Therapeutics

  • Dexcom, Inc.

  • Health Monitor Network

  • Horizon Pharma

  • Insulet Corporation

  • Intarcia Therapeutics, Inc.

  • Lexicon Pharmaceuticals

  • Lilly USA, LLC

  • Mannkind Corporation

  • Medtronics, Inc

  • Merck

  • Merck-Pfizer Diabetes Collaboration

  • Novo Nordisk

  • Pfizer

  • PhRMA

  • Quest Diagnostics

  • Radius Health

  • Sanofi

  • Senseonics Inc

  • Strongbridge Biophama

  • Takeda Pharmaceuticals U.S.A, Inc.

  • Veracyte, Inc.

  • Xeris Pharmaceuticals

To learn more about the CAP or to request more details about joining the CAP, e-mail cap@aace.com.

Resources for Current CAP members

Request More Information